USH2020: The Role of RNA Therapies in Usher Syndrome (USH2A Update)
July 9, 2020
Friedrich Asmus, MD
Watch this presentation in ASL:
Download the transcript
Download the presentation slides
Presentation Summary:
A presentation updating the Usher community of ProQR’s continued clinical progress. The presentation outlines the journey ProQR has been on since it’s founding in 2012 and advancements made since launching the company’s Usher program. The presentation outlines ProQR’s patient-focused RNA therapeutics platform, developing medicines for orphan diseases with well understood genetic causes. The audience will also have an update on ProQR’s latest Usher program data published in March 2020.
Speaker Bio:
Friedrich Asmus, MD is the Vice President of Clinical Development at ProQR. He is a board-certified neurologist and pharmacist. Friedrich spent 12 years in academia, lead research groups for rare genetic movement disorders and botulinum toxin therapy at the Hertie Institute for Clinical Brain Research in Tuebingen, Germany, where he was also Deputy Chair of the Department of General Neurology. In 2011, he joined the pharmaceutical industry with his first position in global clinical development of botulinum toxin A at Merz Pharma, Frankfurt, Germany. In 2013, he started working in ophthalmology global clinical development at Bayer Pharma, Berlin, Germany, and was a key clinical contributor to the development program of the intravitreal anti-VEGF medicine aflibercept in the indication myopic CNV, retinal vein occlusions, and diabetic eye disease. He has published over 50 peer-reviewed full articles in ophthalmology and neurology.
